| Raymond E Poore Jr, MD | |
|
1780 Mcfarland Blvd N, Tuscaloosa, AL 35406-2136 | |
| (205) 345-7351 | |
| (205) 345-8476 |
| Full Name | Raymond E Poore Jr |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 33 Years |
| Location | 1780 Mcfarland Blvd N, Tuscaloosa, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851357933 | NPI | - | NPPES |
| 510-68253 | Other | AL | BCBS OF AL |
| 114258 | Medicaid | AL | |
| 114261 | Medicaid | AL | |
| 511-00713 | Other | AL | BCBS OF AL |
| 114264 | Medicaid | AL | |
| 510-68237 | Other | AL | BCBS OF AL |
| 510-68270 | Other | AL | BCBS OF AL |
| 114255 | Medicaid | AL | |
| 20891 | Other | AL | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 20891 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| D C H Regional Medical Center | Tuscaloosa, AL | Hospital |
| Vaughan Regional Medical Center Parkway Campus | Selma, AL | Hospital |
| Fayette Medical Center | Fayette, AL | Hospital |
| Ssm Health St Mary's Hospital - Madison | Madison, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southeast Physician Network, P.c. | 0840337721 | 25 |
| Dean Health Systems Inc | 7012827983 | 1068 |
News Archive
Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.
Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term clinical outcomes of patients posttransplant who underwent antiviral therapy for recurrent hepatitis C virus (HCV) infection of the liver graft.
The latest research has shown that a simple blood test could detect Alzheimer's disease. Applying the same technology it could also detect hard-to-detect cancers and other diseases. The study reports appeared this Thursday in the journal Cell.
› Verified 9 days ago
| Entity Name | Southeast Physician Network, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598090839 PECOS PAC ID: 0840337721 Enrollment ID: O20091026000423 |
News Archive
Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.
Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term clinical outcomes of patients posttransplant who underwent antiviral therapy for recurrent hepatitis C virus (HCV) infection of the liver graft.
The latest research has shown that a simple blood test could detect Alzheimer's disease. Applying the same technology it could also detect hard-to-detect cancers and other diseases. The study reports appeared this Thursday in the journal Cell.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raymond E Poore Jr, MD 1400 Afflink Pl, Suite 100, Tuscaloosa, AL 35406-2289 Ph: (205) 366-9740 | Raymond E Poore Jr, MD 1780 Mcfarland Blvd N, Tuscaloosa, AL 35406-2136 Ph: (205) 345-7351 |
News Archive
Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.
Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term clinical outcomes of patients posttransplant who underwent antiviral therapy for recurrent hepatitis C virus (HCV) infection of the liver graft.
The latest research has shown that a simple blood test could detect Alzheimer's disease. Applying the same technology it could also detect hard-to-detect cancers and other diseases. The study reports appeared this Thursday in the journal Cell.
› Verified 9 days ago
Kenneth W Aldridge, MD Urology Medicare: Medicare Enrolled Practice Location: 701 University Blvd E, Suite 908, Tuscaloosa, AL 35401 Phone: 205-344-9393 Fax: 205-758-6750 | |
John W Duffy Iii, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1780 Mcfarland Blvd N, Tuscaloosa, AL 35406 Phone: 205-345-7351 Fax: 205-345-8476 | |
Dr. Howard N Winfield, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 701 University Blvd E, Suite 908, Tuscaloosa, AL 35401 Phone: 205-344-9393 Fax: 205-759-7744 | |
Ingrum W Bankston Jr., M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1780 Mcfarland Blvd N, Tuscaloosa, AL 35406 Phone: 205-345-7351 Fax: 205-345-8476 | |
Dr. Winston Murphree Crute, MD Urology Medicare: Medicare Enrolled Practice Location: 1780 Mcfarland Blvd N, Tuscaloosa, AL 35406 Phone: 205-345-7351 Fax: 205-345-8476 | |
Dr. Matthew Robert Thom, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 701 University Blvd E, Suite 908, Tuscaloosa, AL 35401 Phone: 205-344-9393 Fax: 205-759-7744 |